Ricoh USA Spins Off Healthcare 3D Printing Division, Now Called Myrava

Japanese corporations have a long track record of spinning off specialised divisions into standalone businesses, and that pattern just repeated itself on US soil. Ricoh USA has sold its 3D for Healthcare subsidiary to Gary Turner, who led the division as VP and GM, and the company is now operating under the new name Myrava.

What Myrava Actually Does

Under Turner's leadership, the Ricoh 3D for Healthcare unit built a portfolio of FDA clearances centred on patient-specific anatomical models. That work put the division in direct contact with hospitals and surgical teams at the point of care. Myrava's website makes clear this focus will continue: the company is listing co-located manufacturing services alongside clinical partnerships, which signals that the customer relationships Turner cultivated are staying intact.

The AM Center of Excellence at North Carolina State University, opened in 2024, was one of Turner's flagship investments. That facility anchors Myrava in the Charlotte medical innovation corridor, one of the densest clusters of device makers and hospital systems in the United States.

Why Ricoh Let It Go

Bob Lamendola, Ricoh USA's Chief Digital Services and Delivery Officer, was direct about the reasoning: patient-specific medical devices require capabilities that sit outside Ricoh's core business priorities. Selling to the division's own leader rather than an outside competitor protects the investment Ricoh made and removes any risk of the technology walking to a rival.

Turner framed the transaction as a natural evolution. The 3D for Healthcare unit had already been spun into a standalone LLC the year before, giving the team twelve months to prove it could operate independently before the acquisition closed.

The Market Context

Medical 3D printing remains additive manufacturing's most commercially proven segment. Patient-specific surgical guides, implant models, and custom instrumentation all have established reimbursement pathways and clinical evidence bases. The United States dominates the global medical device market, and demand for on-demand, patient-specific parts is still growing.

An independent Myrava with FDA clearances already in hand, existing hospital contracts, and a year of standalone operational experience enters the market in a strong position. The continuity of the business is the key variable here: when a company moves from a corporate parent to independent ownership, customer trust and regulatory standing can shift. In this case, both the buyer and the product team are the same people who built the division.

The broader additive manufacturing industry has been watching medical 3D printing as a stable revenue anchor while industrial and consumer markets cycle through hype. Myrava's independence is a small but meaningful data point: it suggests the segment is mature enough to sustain a dedicated company outside a larger corporate umbrella.